CN109661395A - Pde4抑制剂 - Google Patents

Pde4抑制剂 Download PDF

Info

Publication number
CN109661395A
CN109661395A CN201780051434.6A CN201780051434A CN109661395A CN 109661395 A CN109661395 A CN 109661395A CN 201780051434 A CN201780051434 A CN 201780051434A CN 109661395 A CN109661395 A CN 109661395A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
room temperature
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780051434.6A
Other languages
English (en)
Other versions
CN109661395B (zh
Inventor
罗云富
杨纯道
雷茂义
刘玲
胡国平
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109661395A publication Critical patent/CN109661395A/zh
Application granted granted Critical
Publication of CN109661395B publication Critical patent/CN109661395B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

提供一种PDE4抑制剂，及其在制备治疗与PDE4相关疾病的药物中的应用。具体公开了式(Ⅰ)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201780051434.6A 2016-08-22 2017-08-22 Pde4抑制剂 Active CN109661395B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016107007142 2016-08-22
CN201610700714 2016-08-22
PCT/CN2017/098461 WO2018036469A1 (zh) 2016-08-22 2017-08-22 Pde4抑制剂

Publications (2)

Publication Number Publication Date
CN109661395A true CN109661395A (zh) 2019-04-19
CN109661395B CN109661395B (zh) 2020-09-01

Family

ID=61246401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051434.6A Active CN109661395B (zh) 2016-08-22 2017-08-22 Pde4抑制剂

Country Status (9)

Country Link
US (1) US10662189B2 (zh)
EP (1) EP3502111B1 (zh)
JP (1) JP7029444B2 (zh)
CN (1) CN109661395B (zh)
AU (1) AU2017317123B9 (zh)
CA (1) CA3034785C (zh)
RU (1) RU2743126C9 (zh)
WO (1) WO2018036469A1 (zh)
ZA (1) ZA201901773B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111683949A (zh) * 2018-01-29 2020-09-18 石家庄智康弘仁新药开发有限公司 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112689637B (zh) * 2018-09-13 2023-11-10 橘生药品工业株式会社 咪唑并吡啶酮化合物
US20230141101A1 (en) * 2020-02-24 2023-05-11 Suzhou Longbotai Pharmaceuticals Co., Ltd. Pde4 inhibitor compound and medical use thereof
JP7504822B2 (ja) 2020-03-12 2024-06-24 キッセイ薬品工業株式会社 イミダゾピリジノン化合物を含む医薬組成物
CN112876403B (zh) * 2021-01-27 2022-10-21 成都摩尔生物医药有限公司 一种阿普斯特杂质的制备方法
CA3216489A1 (en) * 2021-04-12 2022-10-20 Impact Therapeutics (Shanghai), Inc. Substituted fused bicyclic compounds as parp inhibitors and the use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
CN101573360A (zh) * 2006-10-19 2009-11-04 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
WO2010030500A1 (en) * 2008-09-09 2010-03-18 Boehringer Ingelheim International Gmbh Aza-benzimidazolone chymase inhibitors
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
CN101111235A (zh) 2004-12-13 2008-01-23 细胞基因公司 含有pde4调节剂的组合物以及它们在治疗或预防气道炎症中的用途
BRPI0608160A2 (pt) 2005-02-16 2010-11-09 Astrazeneca Ab anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
WO2015175956A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
CN101573360A (zh) * 2006-10-19 2009-11-04 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
WO2010030500A1 (en) * 2008-09-09 2010-03-18 Boehringer Ingelheim International Gmbh Aza-benzimidazolone chymase inhibitors
WO2011021678A1 (ja) * 2009-08-21 2011-02-24 武田薬品工業株式会社 縮合複素環化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAY,JONATHAN P.等: ""Elucidation of a Structural Basis for the Inhibitor-Driven,p62(SQSTM1)-Dependent Intracellular Redistribution of cAMP Phosphodiesterase-4A4(PDE4A4)"", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
RAEWYN M. POOLE等: ""Apremilast: First Global Approval"", 《DRUGS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111683949A (zh) * 2018-01-29 2020-09-18 石家庄智康弘仁新药开发有限公司 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法
CN111683949B (zh) * 2018-01-29 2023-03-21 南京明德新药研发有限公司 一种1H-咪唑并[4,5-b]吡啶-2(3H)-酮类化合物的晶型及其制备方法

Also Published As

Publication number Publication date
EP3502111A1 (en) 2019-06-26
WO2018036469A1 (zh) 2018-03-01
EP3502111B1 (en) 2022-07-27
AU2017317123B2 (en) 2021-07-29
RU2019108189A (ru) 2020-09-22
US10662189B2 (en) 2020-05-26
ZA201901773B (en) 2021-08-25
EP3502111A4 (en) 2020-05-20
US20190177318A1 (en) 2019-06-13
AU2017317123B9 (en) 2021-11-25
JP7029444B2 (ja) 2022-04-07
RU2743126C2 (ru) 2021-02-15
AU2017317123A1 (en) 2019-04-11
JP2019528298A (ja) 2019-10-10
RU2743126C9 (ru) 2021-04-27
RU2019108189A3 (zh) 2020-09-22
CA3034785A1 (en) 2018-03-01
CA3034785C (en) 2022-11-15
CN109661395B (zh) 2020-09-01

Similar Documents

Publication Publication Date Title
CN109661395A (zh) Pde4抑制剂
CN104837829B (zh) 抑制剂化合物
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN105001218B (zh) 用于治疗肺动脉高压的双环杂环衍生物
CN105612151B (zh) 具有alk抑制活性的化合物及其制备与用途
CN109071564A (zh) 乙型肝炎病毒表面抗原抑制剂
WO2021143680A1 (zh) 杂芳基类衍生物及其制备方法和用途
CN105209467A (zh) 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
CN106986863A (zh) Dna‑pk抑制剂
CN108047201A (zh) 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN107200749A (zh) Dna‑pk抑制剂
CN102459272A (zh) 对P110δ具有选择性的为PI3K抑制剂的二环嘧啶化合物和使用方法
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
CN104736533B (zh) Vegfr3抑制剂
WO2021139775A1 (zh) 吡啶酮化合物及应用
CN106470992A (zh) 作为pi3k抑制剂的吡啶并[1,2‑a]嘧啶酮类似物
CN109311859A (zh) 用于治疗纤维化和炎性疾病的含杂原子环丁烷取代基的吡啶酮衍生物
TW202100512A (zh) 稠合芳香環類衍生物、其製備方法及其在醫藥上的應用
CN106892948A (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN111560012A (zh) 一种作为irak抑制剂的化合物
CN109715623A (zh) 5-[2-(吡啶-2-基氨基)-1,3-噻唑-5-基]-2,3-二氢-1H-异吲哚-1-酮衍生物及其作为磷脂酰肌醇3-激酶δ和γ的双重抑制剂的用途
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
CN110023286A (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
CN110418790B (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002597

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210719

Address after: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: 050035 Innovation Building, 315 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province, 3rd Floor

Patentee before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd.

TR01 Transfer of patent right